Citations

Showing 10 of 108104 citations.

YM155 Induces DNA Damage and Cell Death in Anaplastic Thyroid Cancer Cells by Inhibiting DNA Topoisomerase IIα at the ATP-Binding Site
Mackay, Ryan P. , Copland, John A. , Mahdavian, Elahe , Xu, Qinqin , Mahdavian, Elahe , Xu, Qinqin , Weinberger, Paul

Mayo Clinic

Molecular Cancer Therapeutics | April 11, 2022 | Volume: 21 | Issue: 6 | Pages: 925-935

10.1158/1535-7163.mct-21-0619 | PMID 35405742 Get It

Abstract Anaplastic thyroid cancer (ATC) is among the most aggressive of human cancers, and currently there are few effective treatments for most patients. YM155, first identified as a survivin inhibitor, was highlighted in a high-throughput screen performed by the National Cancer Institute, killing ATC cells in vitro and in vivo. However, there was no association between survivin expression and response to YM155 in clinical trials, and YM155 has been mostly abandoned for development despite favorable pharmacokinetic and toxicity profiles. Currently, alternative mechanisms are being explored for YM155 by a number of groups. In this study, ATC patient samples show overexpression of topoisomerase Top2α compared with benign thyroid samples and to differentiated thyroid cancers. ATC cell lines that overexpress Top2α are more sensitive to YM155. We created a YM155-resistant cell line, which shows decreased expression of Top2α and is resensitized with Top2α overexpression. Molecular modeling predicts binding for YM155 in the Top2α ATP-binding site and identifies key amino acids for YM155–Top2α interaction. A Top2α mutant abrogates the effect of YM155, confirming the contribution of Top2α to YM155 mechanism of action. Our results suggest a novel mechanism of action for YM155 and may represent a new therapeutic approach for the treatment of ATC.
Fulminant Ehrlichia chaffeensis Infection in a Patient Discovered to Have Indolent Systemic Mastocytosis
Butterfield, Joseph H. , Elliott, Michelle A.

Mayo Clinic

Infectious Diseases in Clinical Practice | April 11, 2022 | Volume: 30 | Issue: 3 | Pages: No page available

10.1097/ipc.0000000000001137 Get It

Abstract Patients with systemic mastocytosis (SM) are at increased risk for anaphylaxis from vespid and honeybee stings. The response of mastocytosis patients to tick-borne infections has not been reported. A 77-year-old woman hospitalized for progressive symptoms of fever, chills, night sweats, and abdominal pain became obtunded and required intubation, support with pressors, treatment for disseminated intravascular coagulation, and resuscitation from 3 episodes of asystole. During her evaluation, bone marrow biopsy revealed heretofore undiagnosed SM. A history of a tick bite 3 weeks previously was elicited when Ehrlichia chaffeensis infection was diagnosed. Institution of treatment with doxycycline led to gradual recovery. Ehrlichia chaffeensis–induced mast cell degranulation was felt to be responsible for many of her symptoms. This case is a cautionary report of the potential danger of tick-borne infection in patients with SM. How widespread this problem occurs is unknown and will depend on future surveillance in endemic areas.
Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange
Moura, Marta Casal , Soler, María José , Sethi, Sanjeev , Fervenza, Fernando C. , Specks, Ulrich , Casal Moura, Marta , Fervenza, Fernando C , Specks, Ulrich , Soler, Maria Jose

Mayo Clinic

Journal of the American Society of Nephrology | April 11, 2022 | Volume: 33 | Issue: 6 | Pages: 1223-1224

10.1681/asn.2022020164 | PMID 35410878 Get It

Factors Associated With Clinician Recommendations for Colorectal Cancer Screening Among Average-Risk Patients: Data From a National Survey
Jacobson, Debra J., Zhu, Xuan , Limburg, Paul J. , Weiser, Emily, Griffin, Joan M. , Rutten, Lila J. Finney

Mayo Clinic

Preventing Chronic Disease | April 11, 2022 | Volume: 19 | Issue: No issue available | Pages: No page available

10.5888/pcd19.210315 | PMID 35420980 Get It

Narcolepsy type 1 comorbid with myasthenia gravis: possible immunological link
Sammak, Sally El , Cipriani, Veronica , Sahni, Ashima , Attarian, Hrayr , El Sammak, Sally

Mayo Clinic

Journal of Clinical Sleep Medicine | April 11, 2022 | Volume: 18 | Issue: 7 | Pages: 1889-1890

10.5664/jcsm.9980 | PMID 35393935 Get It

Perioperative outcomes of patients with restless legs syndrome: a single-center retrospective review
Gali, Bhargavi , Silber, Michael H. , Hanson, Andrew C. , Portner, Erica , Gay, Peter C. , Gay, Peter

Mayo Clinic

Journal of Clinical Sleep Medicine | April 11, 2022 | Volume: 18 | Issue: 7 | Pages: 1841-1846

10.5664/jcsm.10000 | PMID 35393939 Get It

Frontline therapy for advanced hepatocellular carcinoma: an update
Akce, Mehmet , El‐Rayes, Bassel F. , Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S , El-Rayes, Bassel F

Mayo Clinic

Therapeutic Advances in Gastroenterology | April 11, 2022 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17562848221086126 | PMID 35432597 Get It

Hepatocellular carcinoma (HCC) is the fastest increasing cause of cancer-related mortality in the United States and is projected to be the third leading cause of cancer-related mortality in the United States by 2030. Main risk factors include alcoholic cirrhosis, chronic hepatitis B, hepatitis C, and nonalcoholic steatohepatitis (NASH). More than half of the patients have advanced-stage disease at presentation. Currently approved frontline systemic therapy options include sorafenib, lenvatinib, and atezolizumab/bevacizumab. Over the past decade, there has been a significant improvement in survival with a median overall survival of 19.2 months reported with first-line treatment with atezolizumab/bevacizumab. Based on positive results of randomized phase III HIMALAYA trial, durvalumab and tremelimumab combination could become another frontline option. Multiple frontline clinical trials with immune checkpoint inhibitor (ICI) or ICI combined with other novel agents are underway. In the frontline setting, identifying predictive biomarkers for ICI-based or tyrosine kinase (TKI)-based therapy is an unmet need. Subsequent treatment is poorly defined in patients with prior ICI-based therapy since all the available second-line and beyond therapy was studied after first-line sorafenib. Frontline systemic therapy is poorly defined in certain subgroups of HCC such as Child–Pugh B and post-transplant recurrent HCC. The landscape of frontline HCC treatment is rapidly changing, and this article reviews the most recent treatment approaches to frontline therapy for advanced HCC.
A proposal for developing a platform that evaluates algorithmic equity and accuracy
Cerrato, Paul , Pencina, Michael , Halamka, John

Mayo Clinic

BMJ Health & Care Informatics | April 11, 2022 | Volume: 29 | Issue: 1 | Pages: e100423

10.1136/bmjhci-2021-100423 | PMID 35410952 Get It

We are at a pivotal moment in the development of healthcare artificial intelligence (AI), a point at which enthusiasm for machine learning has not caught up with the scientific evidence to support the equity and accuracy of diagnostic and therapeutic algorithms. This proposal examines algorithmic biases, including those related to race, gender and socioeconomic status, and accuracy, including the paucity of prospective studies and lack of multisite validation. We then suggest solutions to these problems. We describe the Mayo Clinic, Duke University, Change Healthcare project that is evaluating 35.1 billion healthcare records for bias. And we propose ‘Ingredients’ style labels and an AI evaluation/testing system to help clinicians judge the merits of products and services that include algorithms. Said testing would include input data sources and types, dataset population composition, algorithm validation techniques, bias assessment evaluation and performance metrics.
Virtual issue: Cranial neuralgias
Robertson, Carrie E. , Robertson, Carrie E

Mayo Clinic

Headache: The Journal of Head and Face Pain | April 11, 2022 | Volume: 62 | Issue: 5 | Pages: 537-539

10.1111/head.14298 | PMID 35404491 Get It